Aceso Life Science Group

What Aceso Life Science Group does

Aceso Life Science Group Limited is a Cayman Islands-incorporated, Hong Kong-listed investment holding company (HKEX: 474) operating three distinct business segments: life science, financial services, and real estate. The company rebranded from Hao Tian Development Group (昊天發展集團) in August 2020 to reflect a strategic pivot into bioscience, although financial services and real estate remain the primary revenue-generating activities.

The life science segment is structured around the Aceso-Promethera Asia joint venture, established in 2019 with Promethera Biosciences and Itochu Corporation. The JV holds exclusive Asian rights to develop, commercialize, and distribute cell-based therapies (HepaStem, H2Stem) and antibody assets (Atrosimab, Novotarg) targeting liver diseases (ACLF, NASH, UCD), autoimmune diseases, and cancers. The segment is pre-revenue and pre-commercial.

The financial services segment is anchored by Hao Tian International Construction Investment Group Limited (HTICI, HKEX: 1341), of which Aceso is the controlling shareholder. HTICI owns licensed Hong Kong entities covering securities trading (Hong Kong, A-shares, US stocks), futures trading, asset management, wealth management, and licensed money lending through Hao Tian Finance (license 1454/2021) and Hao Tian Credit (license 1732/20), which provide equity-pledge, property mortgage, and unsecured loans. The real estate segment comprises two principal assets: the London Commercial Building (55 Mark Lane), a 161,689 sq ft Grade A freehold office generating £6.7M annual rent from insurance-sector tenants, and the Cambodia Comprehensive New City Project, a 17.25 million sq meter special economic zone adjacent to a wharf with land value disclosed at over US$650M.

The company reported FY2025 revenue of HKD 195M, down 44% from HKD 346M in FY2021, with widening losses reaching HKD 1,017M in FY2025. Trading in 474.HK was suspended on July 1, 2026 following a delay in publishing FY2026 annual results. The company employs 101–250 staff and is headquartered in Wan Chai, Hong Kong.

Name

Aceso Life Science Group

Legal name

Aceso Life Science Group Limited

Website

https://acesogrouphk.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Aceso Life Science Group (HKEX: 474) is a Cayman-incorporated Hong Kong-listed holding company with three segments: bioscience (Aceso-Promethera Asia JV licensing cell therapies in Asia), financial services (HTICI, securities, futures, and Hong Kong licensed money lending), and real estate (London Commercial Building and Cambodia SEZ project).

Ownership category

akta.pro rank

Product category

Diversified Investment Holding

NAICS

Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523), Other Financial Investment Activities (5239), Miscellaneous Financial Investment Activities (523999)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211), Investors, Nec (6799), Real Estate Dealers (For Their Own Account) (6532)

akta.pro primary industry

Managed Platforms & Wrap Programs for Private Clients (Model Portfolios, UMA/SMAs) (FSAAABAM)

akta.pro secondary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Licensed money lending
• Cell therapy licensing
• Commercial real estate investment
• Securities and futures trading
• Asset management services

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Financial Services (via HTICI): Revenue derived from professional financial services including securities (Hong Kong, A-share and US-stock trading), futures trading, asset management, wealth management and financial financing through Hao Tian International Financial Holdings Limited (wholly owned by HTICI, 1341.HK).
2. Licensed Money Lending: Hao Tian Finance (license 1454/2021) and Hao Tian Credit (license 1732/20) provide equity-pledge, property mortgage, and unsecured loans to individual and corporate customers, generating interest income.
3. Life Science Licensing & Commercialization: Revenue potential from licensing, development, and commercialization of cell-based therapies (HepaStem, H2Stem) and antibody assets (Atrosimab, Novotarg) for liver diseases and cancers across Asia via the Aceso-Promethera Asia joint venture. Joint venture with Promethera Biosciences holds exclusive rights for Asia.
4. Real Estate Investment Income: Rental income from the London Commercial Building (55 Mark Lane), a freehold Grade A office property of 161,689 sq ft, fully leased to tenants under full insurance and warranty terms at £6,747,002 per annum.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Aceso Life Science Group is a diversified investment holding company operating three segments: (1) Life Science, developing and licensing cell-based therapies (HepaStem, H2Stem, Atrosimab, Novotarg) for liver diseases and cancers across Asia via the Aceso-Promethera Asia joint venture; (2) Financial Services, providing securities, futures, asset/wealth management, and licensed money lending (Hao Tian Finance, Hao Tian Credit) through its listed subsidiary HTICI (1341.HK); and (3) Real Estate Investment, holding the London Commercial Building (55 Mark Lane) and the Cambodia Comprehensive New City Project.

Product overview

Aceso Life Science Group Limited is a diversified investment holding company listed on the Hong Kong Stock Exchange (Stock Code: 474.HK). The company operates a multi-segment business portfolio comprising: (1) Life Science Business as the strategic growth focus, including the Aceso-Promethera Asia joint venture developing cell-based therapies such as HepaStem for liver diseases; (2) Financial Services through its subsidiary HTICI (1341.HK), encompassing Hao Tian International Financial Holdings, Hao Tian Finance (licensed money lender), and Hao Tian Credit (licensed money lender) providing securities, futures, asset management, wealth management, and lending services; and (3) Real Estate Investments including the London Commercial Building (55 Mark Lane) and the Cambodia Comprehensive New City Project in a special economic zone.

Differentiator

Problem solved

Functional benefit

Products and services

• Aceso-Promethera Asia Life Science Business Cell-based therapy development, licensing, and distribution joint venture with Promethera Biosciences and Itochu Corporation, with exclusive Asian rights to HepaStem (cell therapy for ACLF, NASH, UCD), H2Stem, Atrosimab, and Novotarg for liver diseases, autoimmune diseases, and cancers.
• Hao Tian International Financial Holdings Securities and Futures Services Professional financial services including Hong Kong, A-share and US-stock securities trading, futures trading, asset management, wealth management, and financial financing delivered through HTICI subsidiary Hao Tian International Financial Holdings Limited.
• Hao Tian Finance Licensed Money Lending Licensed money lending (money lender license 1454/2021) providing equity pledge, property mortgage, personal and unsecured loans to individual and corporate customers in Hong Kong.
• Hao Tian Credit Licensed Money Lending Licensed money lending (money lender license 1732/20) providing first and second property mortgage loans, land pledge, and equity pledge financing to individual and corporate clients.
• London Commercial Building (55 Mark Lane) Freehold Grade A office property of 161,689 sq ft in London's insurance district, fully leased to office, retail and medical tenants with annual rental income of £6,747,002 and weighted average remaining lease of 6.5 years.
• Cambodia Comprehensive New City Project Urban complex development project in Cambodia's special economic zone (CESIZ) spanning 17,252,519 square meters with land value exceeding US$650 million, planned for smart clean energy industrial parks and high-tech commercial and residential facilities.

Quantifiable outcome

• Total assets exceeded HKD 5 billion as of 31 March 2020
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core and minor.

• Promethera Biosciences S.A/N.V.coreStrategic or Co-development PartnerThe group completed its first round of fundraising towards Promethera Biosciences and established a joint venture, Aceso-Promethera Asia Company Limited. The JV holds exclusive rights for development, commercialization, selling, and distribution of Promethera's cell-based and biological therapies (HepaStem, H2Stem, Atrosimab, Novotarg) for liver diseases (ACLF, NASH, UCD), autoimmune diseases, and cancers in Asia. Promethera Biosciences was founded in 2009 by Professor Etienne Sokal of UCLouvain and is a global innovator in liver therapeutics.
• Itochu CorporationcoreGTM or Marketing PartnerThe JV Company (Aceso-Promethera Asia) will commence joint research with Itochu Corporation on the therapeutic use of certain IP and collaborate on distribution, licensing, and sales of certain products in Asia. Itochu is a major Japanese trading company providing established distribution infrastructure across Asian markets.
• UCLouvain / Sopartec SAminorStrategic or Co-development PartnerPromethera Biosciences was founded in 2009 by Professor Etienne Sokal, a member of the Belgian Royal Academy of Medicine and Professor at UCLouvain, together with UCLouvain TTO Sopartec SA. UCLouvain provides the academic research foundation and Sopartec handles technology transfer.
• Hao Tian International Construction Investment Group Limited (HTICI, 1341.HK)coreOthersAceso Life Science Group is the controlling shareholder of Hao Tian International Construction Investment Group Limited (HTICI, Stock Code: 1341.HK). HTICI is principally engaged in professional financial services and comprehensive urban development and operation, and is the flagship financial platform of the Aceso Group. HTICI owns various financial subsidiaries including securities, futures, credit, and asset management companies.
• Hao Tian International Financial Holdings LimitedcoreOthersWholly-owned by HTICI (1341.HK), Hao Tian International Financial Holdings Limited (HTIF) is a financial investment services company established in early 2016 in Hong Kong, covering securities, futures trading, asset management, wealth management, and financial financing.
• Hao Tian Finance Company LimitedcoreOthersHao Tian Finance was established on 8 December 2011. It is a licensed money lender (money lender license number: 1454/2021) that mainly provides loans to individual and corporate customers through equity pledge of listed companies.
• Hao Tian Credit Company LimitedcoreOthersHao Tian Credit was established on 22 August 2017. It is a licensed money lender (money lender license number: 1732/20) that provides loans to individual and corporate clients through property mortgage, land or equity pledge of listed companies.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Others

• Logan Group Company Limited: Hong Kong-listed diversified group combining property development, financial services and other investments - similar mix and similar Hong Kong financial-press scrutiny as a multi-segment HK-listed holding.

Direct peers

• Hongkong Land Holdings Limited: Asia-based commercial landlord with significant London/financial-district office exposure including insurance-sector tenants; directly comparable to Aceso's 55 Mark Lane freehold and the rent-reversion thesis.
• CASH Financial Services Group: Hong Kong-listed provider of brokerage, margin financing, asset management and money-lending services to HNW clients, directly overlapping with Hao Tian's securities and licensed-lending franchise.
• Hao Tian International Construction Investment Group Limited: The 1341.HK-listed subsidiary of Aceso (474.HK) and its flagship financial platform, providing nearly identical mix of securities, futures, asset management, wealth management and licensed money lending in Hong Kong. Most direct one-to-one comparable.
• Get Nice Holdings Limited: Hong Kong-listed holding running a securities/futures brokerage together with licensed money-lending and property lending businesses that overlap closely with Hao Tian Finance, Hao Tian Credit and HTIF operations.

Broad incumbents

• Sino Biopharmaceutical Limited: Large Hong Kong-listed pharmaceutical group covering oncology, liver and hepatology among other therapeutic areas; provides a scaled incumbent benchmark for Aceso's bioscience ambitions and HepaStem's liver-disease TAM.

Emerging players

• Lee's Pharmaceutical Holdings Limited: Mid-sized Hong Kong-listed pharma with a focus on licensing and developing western/Asian therapies through regional partnerships; structurally similar to the Aceso-Promethera Asia model of in-licensing biotech IP for Asia distribution.
• China Medical System Holdings Limited: Hong Kong-listed specialty pharma with established China sales/medical-promotion infrastructure comparable to the distribution capability the Aceso-Promethera Asia JV seeks to build with Itochu.
• Champion REIT: Hong Kong-listed REIT holding prime commercial assets including Three Garden Road; smaller and more focused than Aceso's real estate sleeve but comparable as a London-adjacent Grade-A commercial landlord.

Regional players

• Far East Consortium Limited: Hong Kong-listed diversified conglomerate with mix of property development, hospitality and financial investments, broadly comparable to Aceso's multi-segment (financial services + real estate) model though with substantially larger operating scale.

Market position

Strengths5 records

Weaknesses6 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aceso Life Science Group